Novo Nordisk to Present New Cardiometabolic Data at EASD 2026, Including Wegovy® Pill and Next-Generation Amylin Treatments

Novo Nordisk announced it will present new data from its cardiometabolic pipeline and portfolio at the upcoming 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 2026. The presentations will include real-world evidence on the Wegovy® pill, data on Wegovy® 7.2 mg and Ozempic® 2.0 mg, and insights into next-generation amylin treatments like CagriSema. The data aims to advance the understanding and treatment of interconnected cardiometabolic diseases such as obesity, type 2 diabetes, cardiovascular, kidney, and fatty liver disease.